Interestingly, the authors found that a single dose of NF-κB decoy ODN delivered via the combination of IP and the AT1002 analog peptide showed improved therapeutic effects against psoriasis, which significantly suppressed epidermal hyperplasia as well as the production of TNF-α and IL-6 mRNA. The gene discussed is NFKB1; the disease is psoriasis.